[go: up one dir, main page]

WO2017005629A1 - Composition destinée à stimuler la pousse des cheveux - Google Patents

Composition destinée à stimuler la pousse des cheveux Download PDF

Info

Publication number
WO2017005629A1
WO2017005629A1 PCT/EP2016/065514 EP2016065514W WO2017005629A1 WO 2017005629 A1 WO2017005629 A1 WO 2017005629A1 EP 2016065514 W EP2016065514 W EP 2016065514W WO 2017005629 A1 WO2017005629 A1 WO 2017005629A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
extract
total weight
relative
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/065514
Other languages
English (en)
Inventor
- Balu
Pushpa LATA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STIGMA Inc
Original Assignee
STIGMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STIGMA Inc filed Critical STIGMA Inc
Publication of WO2017005629A1 publication Critical patent/WO2017005629A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a composition for stimulating hair growth.
  • the composition comprises four key ingredients: coconut oil, Phyllanthus emblica extract, Camellia Sinensis leaf extract and Murraya Koenigii stem extract.
  • the invention further relates to a process for preparing the composition and to the composition for use as a medicament, in particular for use in the treatment of hair loss.
  • Hair loss currently affects millions of the population worldwide. Roughly 50% of women suffer from hair loss and, in men, 40% are reported to have noticeable hair loss by age 35, 65% by age 60, and 80% by age 80. A reduction in the amount or thickness of hair on a person's head can significantly impact upon self-confidence and thus many suffers seek medical treatment for the condition.
  • Normal hair loss is considered to be 100 hairs per day, based on the average scalp containing 100,000 hair follicles. There are many causes of an increased rate of hair loss, these can include medication, stress, poor nutrition, surgery and even hair care techniques. The most common conditions which lead to hair loss are male pattern baldness and female pattern hair loss. Genetics also play an important role.
  • Male-pattern baldness affects around half of all men by the age of fifty. It usually starts around the late twenties or early thirties and most men have some degree of hair loss by their late thirties. It generally follows a pattern of a receding hairline, followed by thinning of the hair on the crown and temples, leaving a horseshoe shape around the back and sides of the head. Sometimes it can progress to complete baldness, although this is uncommon. Male-pattern baldness is hereditary. It's thought to be caused by oversensitive hair follicles, linked to having too much of a certain male hormone.
  • hair loss in older age may be more common, many suffers are young men. Sometimes boys as young as 15 begin to notice the signs and there is some indication that hair loss is becoming more prevalent in younger men. Whilst there are multiple lifestyle and environmental factors that are thought to contribute to an earlier onset of hair loss in men, stress is thought to be a leading cause. Certain other lifestyle choices are also considered to play a part in the development of hair loss in young men, such as smoking. The chemicals and carcinogens found in tobacco are believed to slow down hair growth which leads to thinning hair and can result in significant hair loss if not addressed.
  • Regulational drug use also has the potential to cause hair loss because such drugs can be a shock to the system. Drug use is often accompanied by nutrient depletion and deteriorated health, which means temporary or permanent hair loss is a very probable side effect.
  • Propecia is an oral medicine, the active ingredient of which is Finasteride. This chemical compound is a type II 5oreductase inhibitor. It thus inhibits the enzyme 5oreductase, which converts testosterone to dihydrotestosterone (DHT).
  • DHT dihydrotestosterone
  • the tablets must be taken once a day and if treatment is stopped, the beneficial effects of Propecia start to wear off after six months. By 9 to 12 months all of the beneficial effects will have worn off and the hair loss will be the same as it was before treatment started. Propecia is also solely for use by men.
  • Minoxidil is the active ingredient in Regaine® and is suitable for use by both men and women. This chemical is applied topically to the scalp area twice a day. Its mechanism of action is thought to be due to its action as a vasodilator and potassium channel opener, causing hyperpolarization of cell membranes. By widening blood vessels and opening potassium channels, more oxygen, blood, and nutrients can flow to the hair follicle.
  • Marilex® is a fractionated fish extract with specific lecitan proteoglycans. This product is taken in tablet form twice a day, which presents challenges with patient compliance. The effectiveness is also less than with the more potent chemical products.
  • the present invention is conceived to solve or at least alleviate the problems identified above.
  • An object of the invention is to provide a safe and effective composition which stimulates hair growth, and thus is suitable for the treatment of hair loss.
  • the composition should comprise natural ingredients and be at least as effective as the chemical products currently on the market. It is also desirable to develop a composition which can be administered in a manner which optimises patient compliance.
  • compositions as herein defined.
  • this composition which comprises natural ingredients, is capable of stimulating hair growth and thus may be used in the treatment of hair loss.
  • the composition of the present invention represents a significant improvement compared to those treatments currently available in terms not only of visible results but also patent compliance.
  • the invention provides a composition for stimulating hair growth comprising coconut oil, Phyllanthus emblica extract, Camellia Sinensis leaf extract and Murraya Koenigii stem extract, wherein said coconut oil is present in an amount of at least 50 wt% relative to the total weight of the composition.
  • the invention provides a process for preparing a composition as herein defined, said process comprising the steps:
  • the invention provides a composition as herein defined for use as a medicament.
  • the invention provides the use of a composition as herein defined for stimulating hair growth.
  • the invention provides a composition as herein defined for use in the treatment of hair loss.
  • the present invention provides a method of treating hair loss comprising administering to a patient (e.g. a human) in need thereof a composition as herein defined.
  • the present invention describes a composition for stimulating hair growth.
  • the composition comprises a mixture of natural ingredients, namely coconut oil, Phyllanthus emblica extract, Camellia Sinensis leaf extract and Murraya Koenigii stem extract.
  • the coconut oil is present in an amount of at least 50 wt% relative to the total weight of the composition.
  • the coconut oil is present in an amount of at least 60 wt%, more preferably at least 70 wt%, even more preferably at least 80 wt% relative to the total weight of the composition.
  • the coconut oil is present in an amount of up to 95 wt%, more preferably up to 90 wt%, even more preferably up to 85 wt% relative to the total weight of the composition.
  • the coconut oil is preferably Cocos Nucifera oil.
  • the composition of the invention usually comprises the Phyllanthus emblica extract in an amount of at least 0.5 wt%, preferably at least 1 wt%, more preferably at least 1 .5 wt%, even more preferably at least 2 wt% relative to the total weight of the composition.
  • the Phyllanthus emblica extract is present in an amount of up to 10 wt%, preferably up to 8 wt%, more preferably up to 5 wt%, even more preferably up to 4 wt% relative to the total weight of the composition.
  • the Camellia Sinensis leaf extract may be present in an amount of at least 0.5 wt%, preferably at least 1.0 wt%, more preferably at least 2.5 wt%, even more preferably at least 3.5 wt% relative to the total weight of the composition.
  • the Camellia Sinensis leaf extract is present in an amount of up to 15 wt%, preferably up to 10 wt%, more preferably up to 8 wt%, even more preferably up to 5 wt% relative to the total weight of the composition
  • the Murraya Koenigii stem extract is present in an amount of at least 1 wt%, preferably at least 1 .5 wt%, more preferably at least 2 wt%, even more preferably at least 4 wt% relative to the total weight of the composition.
  • the Murraya Koenigii stem extract is present in an amount of up to 12 wt%, preferably up to 10 wt%, more preferably up to 8 wt%, even more preferably up to 5 wt% relative to the total weight of the composition
  • composition may further comprise other natural ingredients selected from the group consisting of Trigonella Foenum-Graecum seeds, Ocimum Sanctum extract, Aloe Barbadensis extract, Citrus limon juice extract, Rosa canina L. extract, Acorus Calamus rhizome extract, Terminalia Catappa leaf extract, sesame oil (e.g. Sesamum indicum oil), Berberis lyceum extract, Adhatoda vasica extract, Cuscuta reflexa extract, cuminum cyminum oil and Crataegus laevigata extract, or mixtures thereof.
  • other natural ingredients selected from the group consisting of Trigonella Foenum-Graecum seeds, Ocimum Sanctum extract, Aloe Barbadensis extract, Citrus limon juice extract, Rosa canina L. extract, Acorus Calamus rhizome extract, Terminalia Catappa leaf extract, sesame oil (e.g. Sesamum indicum
  • any one or more of these additional ingredients may independently be present in an amount of 0.5 to 10 wt%, preferably 0.8 to 8 wt%, more preferably 1 to 5 wt%, even more preferably 1 .5 to 3 wt% relative to the total weight of the composition.
  • the composition further comprises one or more of Citrus limon juice extract, Cuscuta reflexa extract, Aloe Barbadensis extract, Trigonella Foenum- Graecum seed extract and Ocimum Sanctum extract.
  • the composition further comprises Citrus limon juice extract and/or Cuscuta reflexa extract.
  • composition further comprises
  • Trigonella Foenum-Graecum seeds Ocimum Sanctum extract, Aloe Barbadensis extract, Citrus limon juice extract, Rosa canina L. extract, Acorus Calamus rhizome extract, Terminalia Catappa leaf extract, sesame oil (e.g. Sesamum indicum oil), Berberis lyceum extract, Adhatoda vasica extract, Cuscuta reflexa extract, cuminum cyminum oil and Crataegus laevigata extract.
  • sesame oil e.g. Sesamum indicum oil
  • Berberis lyceum extract Adhatoda vasica extract
  • Cuscuta reflexa extract cuminum cyminum oil and Crataegus laevigata extract.
  • any one or more of these ingredients may independently be present in an amount of 0.5 to 10 wt%, preferably 0.8 to 8 wt%, more preferably 1 to 5 wt%, even more preferably 1.5 to 3 wt% relative to the total weight of the composition.
  • the ingredients of the composition are all natural ingredients, primarily plant extracts.
  • compositions of the invention are typically prepared by mixing the plant extracts in the coconut oil and heating that mixture to a temperature of at least 50 °C.
  • the invention relates to process for preparing a composition as herein defined, said process comprising the steps:
  • the mixture is heated to a temperature of at least 60 °C, more preferably at least 80 °C, even more preferably at least 100 °C.
  • the heating step is performed at temperatures of up to 200 °C, such as up to 150 °C.
  • composition comprises further ingredients in addition to coconut oil, Phyllanthus emblica extract, Camellia Sinensis leaf extract and Murraya Koenigii stem extract, these extra ingredients will be also be added in step (i) above and will form part of the mixture to be heated in step (ii).
  • the filtering, heating and mixing steps may be performed by any known process in the art. Mixing may involve crushing any solid plant extracts. Typically the mixture will be allowed to cool to room temperature (e.g. 18 to 35 °C) between steps (ii) and (iii).
  • compositions of the invention typically consist of the ingredients herein described.
  • the compositions of the invention may be formulated as a pharmaceutical composition, further comprising a pharmaceutically acceptable diluent, excipient and/or carrier.
  • pharmaceutically acceptable refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g. a human).
  • compositions of the present invention can be used in medicine.
  • the invention relates to a composition as herein defined for use as a medicament.
  • the compositions find specific application in the treatment of hair loss.
  • the invention relates to a composition as herein defined for use in the treatment of hair loss.
  • the invention relates to a method of treating hair loss comprising administering to a patient in need thereof a composition as herein defined.
  • the inventors have found a unique mix of natural ingredients, which when administered to a patient can successfully treat hair loss. Without wishing to be bound by theory, the efficacy of the compositions is considered to result from their ability to stimulate new growth at the hair follicle and to strengthen any new and existing hair as it grows.
  • the invention relates to the use a composition as herein defined for stimulating hair growth.
  • compositions described herein are typically administered topically and thus may be prepared in a semi-solid or liquid form suitable for topical administration.
  • Formulations for topical administration can include gels, creams, ointments, hydrogels, pastes, emulsions, sprays, solutions, lotions, topical suspensions, patches, foams, rubbing sticks, electrolysis patchs or other formulation technology exhibiting slow release, adherence to the skin and/or increased penetration.
  • compositions described herein can be prepared as sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles if needed for collateral use of the disclosed compositions and methods, include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
  • Intravenous vehicles if needed for collateral use of the disclosed compositions and methods, include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives can also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
  • the composition is administered topically direct to the scalp.
  • compositions of the present invention may be administered as a monotherapy, or in combination with another agent prescribed for the treatment of hair loss.
  • the term "combination" applied to active ingredients is used herein to define a single pharmaceutical composition (formulation) comprising two active agents (e.g. a pharmaceutical composition comprising the components of the present invention together with another agent prescribed for the treatment of hair loss) or two separate pharmaceutical compositions, each comprising an active agent (e.g. a pharmaceutical composition comprising the components of the present invention invention, and another pharmaceutical composition comprising another agent prescribed for the treatment of hair loss), to be administered conjointly.
  • the term “conjoint administration” is used to refer to administration of a composition of the present invention, and one or more additional active agents (e.g. another agent prescribed for the treatment of hair loss) simultaneously in one composition, or simultaneously in different compositions, or sequentially.
  • additional active agents e.g. another agent prescribed for the treatment of hair loss
  • the sequential administration to be considered “conjoint"
  • the composition of the present invention, and the one or more additional active agents must be administered separately within a time interval which still permits the resultant beneficial effect for treating hair loss.
  • compositions are administered as a monotherapy.
  • Treatment duration may be short-term, e.g., several weeks (for example 8-14 weeks), or long-term until it is deemed administration is no longer necessary.
  • a typical treatment regime will last for at least three months, such as at least six months or at least twelve months.
  • composition of the invention will usually take place on every alternate day for the duration of the treatment, i.e. the composition is administered every second day.
  • the composition is administered in a dose of at least 0.2 ml, preferably at least 0.5 ml, more preferably at least 1 ml, such as at least 1 .5 ml (e.g. 2 ml).
  • the dosage for each administration will not normally exceed 5 ml, more preferably 3 ml. It will be understood that these dosages refer to the amount of composition given to the patient on each administration, e.g. the amount given each alternate day.
  • the composition is applied topically direct to the scalp and allowed to soak in for at least 6 hours, preferably at least 12 hours. The composition may then be washed off.
  • the composition is preferably applied to the patient in the evening, allowed to soak in overnight and then washed off the following morning.
  • the composition of the invention During the first two months of treatment, it is typical for administration of the composition of the invention to be combined with shaving of the area to be treated. Shaving the new hair growth allows the follicles to become stronger, thus increasing the strength of further new hair and is typically carried out at least every 7 days, more preferably at least every 14 days, even more preferably at least every 28 days (e.g. once a month). Usually, after two months of treatment, shaving is often ceased and the new hair is allowed to grow as normal. Administration of the composition may continue after shaving of the area has ceased and will be applied directly to the scalp and areas of new growth.
  • each administration of the composition is preceded by the application of a mild irritant directly to the scalp.
  • a mild irritant include onion juice.
  • This may be in the form of an onion juice extract which has optionally and preferably been mixed with a preservative.
  • the onion juice is obtained directly from a raw onion at the time of application. This is usually carried out by way of direct contact of a peeled and halved raw onion with the scalp area to be treated.
  • composition of the invention is typically used to treat patients aged up to 70 years, such as in the age range 18 to 68 years. It is particularly well suited for patients aged up to 50 years.
  • Group 1 Thirty patients were split into three groups. Group 1 were supplied with a composition according to the invention and raw onion. Group 2 were supplied with a composition according to the invention and an onion juice extract mixed with a preservative. Group 3 were given a placebo. Each group of patients applied the composition (and source of onion juice if applicable) to the scalp every alternate day for 30 days. The results of this study are presented in Tables 1 to 3. Table 1 shows the baseline figures for Groups 1 to 3 and Table 2 shows the same figures after one month of treatment. The integer numbers in the left hand columns of Tables 1 and 2 represent the percentage of each area not covered by hair, so the higher the number the less hair is present. Each area was allocated a weighting according to its size relative to the total of all areas. The percentage figures in the right hand columns represent the weighted percentage of hair loss in each area, which are combined to give a figure for total hair loss. The lower these percentages, the greater the hair coverage.
  • Table 3 shows a comparison between the mean values calculated for the baseline and one month measurements. Group 3, who were administering the placebo saw very little different in hair coverage after one month. Groups 1 and 2 both displayed a mean increase in total hair coverage after this period of at least 10%.
  • Table 1 Baseline Figures for Groups 1 to 3.
  • Table 2 Figures after one month of treatment for Groups 1 to 3.
  • Table 3 Comparison of mean data at baseline and after one month of treatment for Groups 1 to 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pour stimuler la pousse des cheveux comprenant de l'huile de noix de coco, de l'extrait de Phyllanthus emblica, de l'extrait de feuille de Camellia Sinensis et de l'extrait de tige de Murraya Koenigii, ladite huile de noix de coco étant présente dans une proportion d'au moins 50 % en poids par rapport au poids total de la composition.
PCT/EP2016/065514 2015-07-03 2016-07-01 Composition destinée à stimuler la pousse des cheveux Ceased WO2017005629A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1511697.3A GB2541158A (en) 2015-07-03 2015-07-03 Composition
GB1511697.3 2015-07-03

Publications (1)

Publication Number Publication Date
WO2017005629A1 true WO2017005629A1 (fr) 2017-01-12

Family

ID=54013457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/065514 Ceased WO2017005629A1 (fr) 2015-07-03 2016-07-01 Composition destinée à stimuler la pousse des cheveux

Country Status (2)

Country Link
GB (1) GB2541158A (fr)
WO (1) WO2017005629A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019034347A1 (fr) * 2017-08-17 2019-02-21 Unilever N.V. Composition à usage topique pour ses bénéfices anti-âge
WO2019096570A1 (fr) * 2017-11-14 2019-05-23 Unilever N.V. Composition de shampooing

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022137257A1 (fr) * 2020-12-22 2022-06-30 Diabliss Consumer Products Pvt Ltd Formulation nutraceutique ayant des propriétés organoleptiques améliorées utilisées pour des soins capillaires et du cuir chevelu

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3246265A1 (de) * 1982-12-14 1984-06-14 Veronica 8000 München Rudder Dermatotherapeutikum zur anregung und foerderung des haarwuchses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3974003B2 (ja) * 2002-09-02 2007-09-12 ポーラ化成工業株式会社 育毛素材及びそれを含有する皮膚外用剤
JP2005145902A (ja) * 2003-11-17 2005-06-09 Nippon Menaade Keshohin Kk テストステロン−５α−レダクターゼ阻害剤
KR100664400B1 (ko) * 2005-07-01 2007-01-04 동아제약주식회사 탈모예방 및 양모(養毛) 조성물
JP2007153775A (ja) * 2005-12-02 2007-06-21 Nisshin Sugar Mfg Co Ltd 育毛剤
KR101606393B1 (ko) * 2011-06-27 2016-03-28 (주)아모레퍼시픽 화산석 송이를 함유하는 화장료 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3246265A1 (de) * 1982-12-14 1984-06-14 Veronica 8000 München Rudder Dermatotherapeutikum zur anregung und foerderung des haarwuchses

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE GNPD [online] MINTEL; 1 April 2013 (2013-04-01), BIO ORGANIC & NATURAL: "Organic Hair Nourisher", XP002760266, Database accession no. 2032060 *
DATABASE GNPD [online] MINTEL; 1 January 2014 (2014-01-01), FLEMINGO MARKETING & TRADING: "Thejomayi Herbal Hair Care Oil", XP002760265, Database accession no. 2281375 *
DATABASE GNPD [online] MINTEL; 1 January 2014 (2014-01-01), K.P. NAMBOODIRI'S AYURVEDICS: "Ayurvedic Hair Care Oil", XP002760264, Database accession no. 2276539 *
DATABASE TKDL [online] 1 January 1975 (1975-01-01), SAHIB ABDULLA: "Kundhal Valar Thylam", XP002760267, Database accession no. JK01/240 *
KWON ET AL: "Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG)", PHYTOMEDICINE, GUSTAV FISCHER VERLAG, STUTTGART, DE, vol. 14, no. 7-8, 19 July 2007 (2007-07-19), pages 551 - 555, XP022163619, ISSN: 0944-7113, DOI: 10.1016/J.PHYMED.2006.09.009 *
LIPI PURWAL ET AL: "Development and Evaluation of Herbal Formulations for Hair Growth", E-JOURNAL OF CHEMISTRY, vol. 5, no. 1, 1 January 2008 (2008-01-01), IN, pages 34 - 38, XP055291317, ISSN: 0973-4945, DOI: 10.1155/2008/674598 *
NAPHATSORN KUMAR ET AL: "5[alpha]-reductase inhibition and hair growth promotion of some Thai plants traditionally used for hair treatment", JOURNAL OF ETHNOPHARMACOLOGY, vol. 139, no. 3, 1 February 2012 (2012-02-01), pages 765 - 771, XP055183186, ISSN: 0378-8741, DOI: 10.1016/j.jep.2011.12.010 *
R KAUSHIK ET AL: "ALOPECIA: HERBAL REMEDIES", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, vol. 2, no. 7, 1 July 2011 (2011-07-01), Pnachkula (HR), pages 1631 - 1637, XP055142386, ISSN: 2320-5148 *
YOSHIMI NIWANO ET AL: "Extensive screening for herbal extracts with potent antioxidant properties", JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, vol. 48, no. 1, 1 January 2010 (2010-01-01), pages 78 - 84, XP055188875, ISSN: 0912-0009, DOI: 10.3164/jcbn.11-013FR *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019034347A1 (fr) * 2017-08-17 2019-02-21 Unilever N.V. Composition à usage topique pour ses bénéfices anti-âge
WO2019096570A1 (fr) * 2017-11-14 2019-05-23 Unilever N.V. Composition de shampooing

Also Published As

Publication number Publication date
GB2541158A (en) 2017-02-15
GB201511697D0 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
KR101698922B1 (ko) 발모 및 육모 촉진용 조성물
US20040258765A1 (en) Method for treatment of sores and lesions of the skin
CN106061474B (zh) 用类单萜治疗脱发的方法
US6465514B1 (en) Methods and compositions for the promotion of hair growth
WO2017005629A1 (fr) Composition destinée à stimuler la pousse des cheveux
US20130323334A1 (en) Use Of Compositions For Preventing Chemotherapy And Radiotherapy Induced Alopecia (CRIA), Reducing CRIA Impact And Improving The Appearance Of Hair Re-Growth After CRIA
JP3510751B2 (ja) 美白化粧料
JP2004067634A5 (fr)
CN106937957A (zh) 一种用于治疗雄激素性脱发的配方、洗发液以及该配方的使用方法
US20080267899A1 (en) Plant extract composition for hair growth
WO2013078754A1 (fr) Solution de stimulation de la croissance capillaire comprenant du dioxyde de chlore, procédé de préparation et procédé d'utilisation associés
US20050152993A1 (en) Composition for and method of treatment for skin ailments
KR101574555B1 (ko) 진세노사이드 Rg3, Rg5 및 Rk1을 유효성분으로 포함하는 발모, 육모촉진 및 탈모 방지용 화장료조성물
KR100603122B1 (ko) 생약재 조성물 및 이를 포함하는 탈모방지 및 모발생장 촉진용 약학적 조성물
KR101742819B1 (ko) 양모 또는 발모 촉진용 한약재 추출물 및 이를 포함하는 화장료 조성물
CN113730499B (zh) 一种中药组合物在制备治疗斑秃药物中的应用
JP2002526395A (ja) 化粧品あるいは皮膚科製品におけるボルド抽出物の使用
US20060073224A1 (en) Method of preparing Dioscorea tincture and uses thereof
KR20020008268A (ko) 오배자 추출물을 함유하는 테스토스테론 5알파-리덕타아제저해제
KR100476069B1 (ko) １，２－디티올티온 유도체를 함유하는 발모촉진용 또는탈모방지용 조성물
CN112915176B (zh) 一种防治脱发的草豆蔻组合物
CN114831920A (zh) 一种外用新型快速防脱止脱去屑养发生发组合物
WO2023230449A2 (fr) Composition et procédés de repousse des cheveux
KR960015725B1 (ko) 모발처리용 조성물
KR20240097477A (ko) 천연 혼합 추출물을 유효성분으로 함유하는 모근 강화 화장료 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16733107

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16733107

Country of ref document: EP

Kind code of ref document: A1